1. Home
  2. NSP vs RLMD Comparison

NSP vs RLMD Comparison

Compare NSP & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Insperity Inc.

NSP

Insperity Inc.

HOLD

Current Price

$31.73

Market Cap

819.5M

ML Signal

HOLD

Logo Relmada Therapeutics Inc.

RLMD

Relmada Therapeutics Inc.

HOLD

Current Price

$7.50

Market Cap

784.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NSP
RLMD
Founded
1986
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
819.5M
784.6M
IPO Year
1996
2012

Fundamental Metrics

Financial Performance
Metric
NSP
RLMD
Price
$31.73
$7.50
Analyst Decision
Hold
Strong Buy
Analyst Count
3
5
Target Price
$47.67
$12.40
AVG Volume (30 Days)
816.6K
1.4M
Earning Date
04-30-2026
05-11-2026
Dividend Yield
8.30%
N/A
EPS Growth
N/A
45.28
EPS
N/A
N/A
Revenue
$6,812,000,000.00
$13,070.00
Revenue This Year
$3.45
N/A
Revenue Next Year
$6.95
N/A
P/E Ratio
N/A
N/A
Revenue Growth
3.51
154.83
52 Week Low
$18.57
$0.27
52 Week High
$80.45
$7.94

Technical Indicators

Market Signals
Indicator
NSP
RLMD
Relative Strength Index (RSI) 67.21 61.67
Support Level $31.00 $3.49
Resistance Level $39.86 $7.41
Average True Range (ATR) 1.75 0.45
MACD 0.47 -0.04
Stochastic Oscillator 96.55 65.50

Price Performance

Historical Comparison
NSP
RLMD

About NSP Insperity Inc.

Insperity Inc is a company that provides a wide range of human resources and business solutions designed to help businesses improve their performance. Small and midsize enterprises are the company's primary target customers. Majority of the company's products are offered through the company's Workforce Optimization and Workforce Synchronization solutions, which comprise various human resource functions, such as payroll and employment administration, employee benefits and compensation, government compliance, performance management, training and development services, and human capital management. The company generates all of its revenue in the United States.

About RLMD Relmada Therapeutics Inc.

Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.

Share on Social Networks: